Inositol Niacinate
CAS 6556-11-2
Inositol Niacinate (CAS 6556-11-2) is a Phase 2 pharmaceutical compound with 0 bioactivity targets and 3 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Clinical Development Phase
Highest clinical development phase rendered from the matched compound identifier rows.
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
Drug Names / RxNorm
Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.
| Name | RxCUI | Type | Source |
|---|---|---|---|
| inositol niacinate | 27604 | PIN | RXNORM |
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Inositol Niacinate used for in pharmaceutical contexts?
Inositol Niacinate (CAS 6556-11-2) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for Inositol Niacinate?
Inositol Niacinate has 3 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Cataract, Lymphocyte count increased, Product dose omission in error. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Inositol Niacinate also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for Inositol Hexanicotinate with EU status "permitted".
What clinical phase is Inositol Niacinate in?
Inositol Niacinate is rendered with ChEMBL max phase 2.